Allan James
About
Allan James is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Allan James has authored 30 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Otorhinolaryngology, 12 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Allan James's work include Head and Neck Cancer Studies (15 papers), Glioma Diagnosis and Treatment (7 papers) and Head and Neck Surgical Oncology (5 papers). Allan James is often cited by papers focused on Head and Neck Cancer Studies (15 papers), Glioma Diagnosis and Treatment (7 papers) and Head and Neck Surgical Oncology (5 papers). Allan James collaborates with scholars based in United Kingdom, United States and Germany. Allan James's co-authors include Catherine McBain, Sarah Jefferies, Claire Paterson, Derek Grose, Anthony J. Chalmers, Mohammed Rizwanullah, Sarah Halford, William Stewart, Caroline Kelly and Christina Wilson and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.
In The Last Decade
Allan James
30 papers receiving 431 citations
Peers
Allan James
Huan-Huan Wang China
Qingting Huang China
Anca‐L. Grosu Germany
M. Soike United States
Rubén Fragoso United States
Lu‐Jun Zhao China
Steven McGraw United States
Danielle Gioioso United States
Julian Mangesius Austria
Willem DuBois United States
Citations per year, relative to Allan James Allan James (= 1×)
peers
Huan-Huan Wang
Countries citing papers authored by Allan James
Since
Specialization
Citations
This map shows the geographic impact of Allan James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allan James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allan James more than expected).
Fields of papers citing papers by Allan James
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Allan James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allan James. The network helps show where Allan James may publish in the future.
Co-authorship network of co-authors of Allan James
This figure shows the co-authorship network connecting the top 25 collaborators of Allan James. A scholar is included among the top collaborators of Allan James based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allan James. Allan James is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chalmers, Anthony J., et al.. (2024). Dosimetric comparison of hippocampal-sparing technologies in patients with low-grade glioma. Neuro-Oncology Advances. 6(1). vdae131–vdae131.
2.
Noble, David J., Allan James, Derek Grose, et al.. (2024). The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland. Clinical Oncology. 36(5). 287–299.
3.
Derby, Sarah, Mark R. Jackson, Karin Williams, et al.. (2024). Concurrent Olaparib and Radiation Therapy in Older Patients With Newly Diagnosed Glioblastoma: The Phase 1 Dose-Escalation PARADIGM Trial. International Journal of Radiation Oncology*Biology*Physics. 118(5). 1371–1378.
4.
Schipani, Stefano, et al.. (2023). The Effects of Human Papillomavirus Status and Treatment on the Positive Predictive Value of Post-radiotherapy 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Advanced Head and Neck Squamous Cell Carcinoma. Clinical Oncology. 35(12). e699–e707.
5.
Derby, Sarah, Jon Stobo, Allan James, et al.. (2023). OS09.3.A FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM). Neuro-Oncology. 25(Supplement_2). ii20–ii21.
6.
McMahon, Jeremy, Robert Pitts, Allan James, et al.. (2020). Postoperative risk stratification in oral squamous cell carcinoma. British Journal of Oral and Maxillofacial Surgery. 58(4). 462–468.
7.
Stobo, David, Allan James, Derek Grose, et al.. (2020). Positron Emission Tomography-Computed Tomography Surveillance after (Chemo)Radiotherapy in Advanced Head and Neck Squamous Cell Cancer: Beyond the PET-NECK Protocol. Clinical Oncology. 32(10). 665–673.
8.
Stobo, David, Allan James, Derek Grose, et al.. (2019). 12 week PET-CT has low positive predictive value for nodal residual disease in human papillomavirus-positive oropharyngeal cancers. Oral Oncology. 97. 76–81.
9.
Paterson, Claire, Brian T. Caldwell, S.M. Clark, et al.. (2019). Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck. British Journal of Oral and Maxillofacial Surgery. 57(10). 1119–1125.
10.
Butler, Holly J., Ruth Board, Paul M. Brennan, et al.. (2018). Health economic evaluation of a serum-based blood test for brain tumour diagnosis: exploration of two clinical scenarios. BMJ Open. 8(5). e017593–e017593.
11.
Paterson, Claire, J. E. Foster, M. McJury, et al.. (2017). Study of diffusion weighted MRI as a predictive biomarker of response during radiotherapy for high and i ntermediate risk squamous cell cancer of the oropharynx: The MeRInO study. Clinical and Translational Radiation Oncology. 2. 13–18.
12.
Short, Susan, Allan James, Catherine McBain, et al.. (2017). PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology. 8. 12–16.
13.
Rampling, R., Paul Mulholland, Allan James, et al.. (2016). A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research. 22(19). 4776–4785.
14.
Wilson, Christina, Claire Paterson, Allan James, et al.. (2016). Validation of a Magnetic Resonance Imaging-based Auto-contouring Software Tool for Gross Tumour Delineation in Head and Neck Cancer Radiotherapy Planning. Clinical Oncology. 29(1). 60–67.
15.
Halford, Sarah, R. Rampling, Allan James, et al.. (2014). Final Results from a Cancer Research Uk First in Man Phase I Trial of Ima950 (A Novel Multi Peptide Vaccine) Plus Gm-Csf in Patients with Newly Diagnosed Glioblastoma. Annals of Oncology. 25. iv364–iv364.
16.
Roxburgh, Patricia, James Paul, Allan James, et al.. (2014). A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. Cancer Chemotherapy and Pharmacology. 74(1). 131–139.
17.
McJury, M., Lye Mun Tho, Derek Grose, et al.. (2013). The influence of MRI scan position on patients with oropharyngeal cancer undergoing radical radiotherapy. Radiation Oncology. 8(1). 129–129.
18.
Muirhead, R., et al.. (2013). Is There a Role for Radiotherapy in the Primary Management of Primary Central Nervous System Lymphoma? A Single-centre Case Series. Clinical Oncology. 25(7). 400–405.
19.
Smillie, Ian, et al.. (2013). Head drop syndrome secondary to multimodality treatments for head and neck cancer. The Laryngoscope. 123(4). 938–941.
20.
James, Allan, et al.. (2012). Quantitative comparison of volumetric modulated arc therapy and intensity modulated radiotherapy plan quality in sino-nasal cancer. Journal of Medical Physics. 37(1). 8–8.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Huan-Huan Wang Breakdown of academic impact, for papers by Qingting Huang Breakdown of academic impact, for papers by Anca‐L. Grosu Breakdown of academic impact, for papers by M. Soike Breakdown of academic impact, for papers by Rubén Fragoso Breakdown of academic impact, for papers by Lu‐Jun Zhao Breakdown of academic impact, for papers by Steven McGraw Breakdown of academic impact, for papers by Danielle Gioioso Breakdown of academic impact, for papers by Julian Mangesius Breakdown of academic impact, for papers by Willem DuBois